Androgen receptor (AR), a member of the NR superfamily, plays a key role in the onset and progression of prostate cancer (5,6), and numerous synthetic AR antagonists have been developed to inhibit the action of endogenous AR ligands (i.e. androgens) (7,8). This evidence concerns the gene AR and prostate carcinoma.